FDA Takes Exelixis Cancer Drug Off Advisory Group Meeting, Approval Date Stays as Nov. 29

Exelixis’ experimental cancer drug cabozantinib has been removed from the agenda of a Food and Drug Administration advisory committee meeting, the company said, but the drug’s potential approval date has not changed.
San Francisco Business Times